Thrombosis in multiple myeloma

References

• Osman K, Comenzo R, Rajkumar SV. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N. Engl. J. Med.344(25), 1951–1952 (2001).
   PubMed Web of Science ®Google Scholar
• Tricot G. Multiple myeloma and other plasma cell disorders. In: Hematology. Basic Principles and Practice (4th Edition). Hoffman R (Ed.). Elsevier Churchill Livingston Editions, London, UK Chapter 83, 1501–1535 (2005).
   Google Scholar
• Baron JA, Gridley G, Weiderpass E, Nyren O, Linet M. Venous thromboembolism and cancer. Lancet351(9109), 1077–1080 (1998).
   PubMed Web of Science ®Google Scholar
• Prandoni P, Lensing AW, Buller HR et al. Deep-vein thrombosis and incidence of subsequent symptomatic cancer. N. Engl. J. Med.327(16), 1128–1133 (1992).
   PubMed Web of Science ®Google Scholar
• Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N. Engl. J. Med.343(25), 1846–1850 (2000).
   PubMed Web of Science ®Google Scholar
• Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest124(3 Suppl.), S58–S68 (2003).
   PubMed Web of Science ®Google Scholar
• Sallah S, Husain A, Wan J, Vos P, Nguyen NP. The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. Ann. Oncol.15(10), 1490–1494 (2004).
   PubMedGoogle Scholar
• Srkalovic G, Cameron MG, Rybicki L et al. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer101(3), 558–566 (2004).
   PubMed Web of Science ®Google Scholar
• Barlogie B, Desikan R, Eddlemon P et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a Phase 2 study of 169 patients. Blood98(2), 492–494 (2001).
   PubMed Web of Science ®Google Scholar
• Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation107(23 Suppl. 1), I17–I21 (2003).
   Web of Science ®Google Scholar
• D’Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl Acad. Sci. USA91(9), 4082–4085 (1994).
   PubMed Web of Science ®Google Scholar
• Sheskin J. Thalidomide in the treatment of lepra reactions. Clin. Pharmacol. Ther6, 303–306 (1965).
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med.341(21), 1565–1571 (1999).
   PubMed Web of Science ®Google Scholar
• Tosi P, Zamagni E, Cellini C et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica87(4), 408–414 (2002).
   PubMed Web of Science ®Google Scholar
• Kumar S, Gertz MA, Dispenzieri A et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin. Proc.78(1), 34–39 (2003).
   PubMed Web of Science ®Google Scholar
• Cavo M, Zamagni E, Tosi P et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica89(7), 826–831 (2004).
   PubMed Web of Science ®Google Scholar
• Zangari M, Anaissie E, Barlogie B et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood98(5), 1614–1615 (2001).
   PubMed Web of Science ®Google Scholar
• Bartlett JB, Michael A, Clarke IA et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br. J. Cancer90(5), 955–961 (2004).
   PubMed Web of Science ®Google Scholar
• Zangari M, Elice F, Tricot G. Immunomodulatory drugs in multiple myeloma. Expert Opin. Investig. Drugs14(11), 1411–1418 (2005).
   PubMed Web of Science ®Google Scholar
• Weber DM, Chen C, Niesvizky R et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refactory multiple myeloma (MM): results of a North American Phase III study (MM-009). J. Clin. Oncol.24(S18) (2006) (Abstract 7521).
   Google Scholar
• Dimopoulos MA, Spencer A, Attal M et al. Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a Phase 3 study (MM-010). Blood106, (2005) (Abstract 6).
   Google Scholar
• Donati MB, Falanga A. Pathogenetic mechanism of thrombosis in malignancy. Acta Haematol.106(1–2), 18–24 (2001).
   PubMed Web of Science ®Google Scholar
• Gouin-Thibault I, Achkar A, Samama MM. The thrombophilic state in cancer patients. Acta Haematol.106(1–2), 33–42 (2001).
   PubMed Web of Science ®Google Scholar
• Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia4(6), 465–473 (2002).
   PubMed Web of Science ®Google Scholar
• Zangari M, Saghafifar F, Mehta P, Barlogie B, Fink L, Tricot G. The blood coagulation mechanism in multiple myeloma. Semin. Thromb. Hemost.29(3), 275–282 (2003).
   PubMed Web of Science ®Google Scholar
• Zangari M, Siegel E, Barlogie B et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood100(4), 1168–1171 (2002).
   PubMed Web of Science ®Google Scholar
• Kaushal V, Kaushal GP, Melkaveri SN, Mehta P. Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology. J. Thromb. Haemost.2(2), 327–334 (2004).
   PubMed Web of Science ®Google Scholar
• Zangari M, Barlogie B, Thertulien R et al. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin. Lymphoma4(1), 32–35 (2003).
   PubMedGoogle Scholar
• Elice F, Fink L, Tricot G, Barlogie B, Zangari M. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br. J. Haematol.134(4), 399–405 (2006).
   PubMed Web of Science ®Google Scholar
• Otterson GA, Monahan BP, Harold N, Steinberg SM, Frame JN, Kaye FJ. Clinical significance of the FV:Q506 mutation in unselected oncology patients. Am. J. Med.101(4), 406–412 (1996).
   PubMedGoogle Scholar
• Santos AB, Llamas P, Roman A et al. Evaluation of thrombophylic states in myeloma patients receiving thalidomide: a reasonable doubt. Br. J. Haematol.122(1), 159–160 (2003).
   PubMedGoogle Scholar
• Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet355(9200), 248–250 (2000).
   PubMed Web of Science ®Google Scholar
• Amrani DL. Regulation of fibrinogen biosynthesis: glucocorticoid and interleukin-6 control. Blood Coagul. Fibrinolysis1(4–5), 443–446 (1990).
   PubMedGoogle Scholar
• Stirling D, Hannant WA, Ludlam CA. Transcriptional activation of the factor VIII gene in liver cell lines by interleukin-6. Thromb. Haemost.79(1), 74–78 (1998).
   PubMedGoogle Scholar
• Minnema MC, Fijnheer R, De Groot PG, Lokhorst HM. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J. Thromb. Haemost.1(3), 445–449 (2003).
   PubMed Web of Science ®Google Scholar
• Esmon CT. Possible involvement of cytokines in diffuse intravascular coagulation and thrombosis. Baillieres Best Pract. Res. Clin. Haematol.12(3), 343–359 (1999).
   PubMed Web of Science ®Google Scholar
• Deitcher SR, Erban JK, Limentani SA. Acquired free protein S deficiency associated with multiple myeloma: a case report. Am. J. Hematol.51(4), 319–323 (1996).
   PubMed Web of Science ®Google Scholar
• Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc. Natl Acad. Sci. USA90(3), 1004–1008 (1993).
   PubMed Web of Science ®Google Scholar
• Bertina RM, Koeleman BP, Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature369(6475), 64–67 (1994).
   PubMed Web of Science ®Google Scholar
• Green D, Maliekel K, Sushko E, Akhtar R, Soff GA. Activated-protein-C resistance in cancer patients. Haemostasis27(3), 112–118 (1997).
   PubMedGoogle Scholar
• Haim N, Lanir N, Hoffman R, Haim A, Tsalik M, Brenner B. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am. J. Med.110(2), 91–96 (2001).
   PubMed Web of Science ®Google Scholar
• Zangari M, Saghafifar F, Anaissie E et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul. Fibrinolysis13(3), 187–192 (2002).
   PubMed Web of Science ®Google Scholar
• Hugo JZ, Jeane DM. Acquired activated protein C resistance and thrombosis in multiple myeloma patients. Thromb. J.4, 11 (2006).
   PubMedGoogle Scholar
• Gabriel DA, Smith LA, Folds JD, Davis L, Cancelosi SE. The influence of immunoglobulin (IgG) on the assembly of fibrin gels. J. Lab. Clin. Med.101(4), 545–552 (1983).
   PubMedGoogle Scholar
• Carr ME Jr, Dent RM, Carr SL. Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma. J. Lab. Clin. Med.128(1), 83–88 (1996).
   PubMed Web of Science ®Google Scholar
• Yagci M, Sucak GT, Haznedar R. Fibrinolytic activity in multiple myeloma. Am. J. Hematol.74(4), 231–237 (2003).
   PubMed Web of Science ®Google Scholar
• van Marion AM, Auwerda JJ, Minnema MC et al. Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis. Thromb. Haemost.94(6), 1341–1343 (2005).
   PubMed Web of Science ®Google Scholar
• Yasin Z, Quick D, Thiagarajan P, Spoor D, Caraveo J, Palascak J. Light-chain paraproteins with lupus anticoagulant activity. Am. J. Hematol.62(2), 99–102 (1999).
   PubMed Web of Science ®Google Scholar
• Takamiya O, Machida S, Okuda M, Nojima J, Koreeda C, Kubara K. A non-immunological phospholipid-dependent coagulation inhibitor associated with IgGλ-type multiple myeloma. Am. J. Hematol.75(1), 34–39 (2004).
   PubMed Web of Science ®Google Scholar
• Ward CM, Yen T, Harvie R, Pavlakis N. Elevated levels of factor VIII and von Willebrand factor after thalidomide treatment for malignancy: relationship to thromboembolic events. Hematol. J.4(Suppl. 1) (2003) (Abstract 265).
   Google Scholar
• Corso A, Lorenzi A, Terulla V et al. Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Ann. Hematol.83(9), 588–591 (2004).
   PubMed Web of Science ®Google Scholar
• Bertolini F, Mingrone W, Alietti A et al. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. Ann. Oncol.12(7), 987–990 (2001).
   PubMed Web of Science ®Google Scholar
• Neben K, Moehler T, Kraemer A et al. Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br. J. Haematol.115(3), 605–608 (2001).
   PubMed Web of Science ®Google Scholar
• Geerts WH, Pineo GF, Heit JA et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest126(3 Suppl.), S338–S400 (2004).
   PubMedGoogle Scholar
• Kakkar AK, Levine MN, Kadziola Z et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J. Clin. Oncol.22(10), 1944–1948 (2004).
   PubMed Web of Science ®Google Scholar
• Cunningham MS, White B, Hollywood D, O’Donnell J. Primary thromboprophylaxis for cancer patients with central venous catheters – a reappraisal of the evidence. Br. J. Cancer94(2), 189–194 (2006).
   PubMedGoogle Scholar
• Perret-Guillaume C, Wahl DG. Low-dose warfarin in atrial fibrillation leads to more thromboembolic events without reducing major bleeding when compared to adjusted-dose – a meta-analysis. Thromb. Haemost.91(2), 394–402 (2004).
   PubMedGoogle Scholar
• Lee AY, Levine MN, Baker RI et al. Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med.349(2), 146–153 (2003).
   PubMed Web of Science ®Google Scholar
• Baz R, Li L, Kottke-Marchant K et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin. Proc.80(12), 1568–1574 (2005).
   PubMed Web of Science ®Google Scholar
• Zangari M, Barlogie B, Anaissie E et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br. J. Haematol.126(5), 715–721 (2004).
   PubMed Web of Science ®Google Scholar
• Weber D, Rankin K, Gavino M et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J. Clin. Oncol.21, 16–19 (2003).
   PubMed Web of Science ®Google Scholar
• Minnema MC, Breitkreutz I, Auwerda JJ et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia18(12), 2044–2046 (2004).
   PubMed Web of Science ®Google Scholar
• Hussein MA. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thromb. Haemost.95(6), 924–930 (2006).
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Hayman SR, Lacy MQ et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood106(13), 4050–4053 (2005).
   PubMed Web of Science ®Google Scholar
• Zonder JA, Barlogie B, Durie BG, McCoy J, Crowley J, Hussein MA. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood108(1), 403 (2006).
   PubMed Web of Science ®Google Scholar
• Baz R, Walker E, Karam M et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann. Oncol.17(12), 1766–1771 (2006).
   PubMed Web of Science ®Google Scholar
• Zangari M, Barlogie B, Cavallo F et al. Effect on survival of treatment associated venous thromboembolism in newly diagnosed multiple myeloma patients. Blood Coagul. Fibrinolysis (2006) (In Press).
   Google Scholar
• Baz R, Hussein MA Does low-dose aspirin have antineoplastic effects in multiple myeloma? Br. J. Haematol.134(3), 349–350 (2006).
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Gertz MA, Lacy MQ et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia17(4), 775–779 (2003).
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol.24(3), 431–436 (2006).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Rus C, Zeldis JB, Rodeghiero F, Boccadoro M. Italian Multiple Myeloma Network, Gimema. Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide. J. Thromb. Haemost.4(8), 1842–1845 (2006).
   PubMed Web of Science ®Google Scholar
• Oakervee H, Baugh H, Boots M et al. A study of the safety and efficacy of oral melphalan, prednisolone and thalidomide (MPT) in the treatment of multiple myeloma: a UK Myeloma Forum Pilot Study. Br. J. Haematol.117 (Suppl. 1), 66 (2002).
   Google Scholar
• Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br. J. Haematol.121(5), 768–771 (2003).
   PubMed Web of Science ®Google Scholar
• Urbauer E, Kaufmann H, Nosslinger T, Raderer M, Drach J. Thromboembolic events during treatment with thalidomide. Blood99(11), 4247–4248 (2002).
   PubMed Web of Science ®Google Scholar
• Moehler TM, Neben K, Benner A et al. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood98(13), 3846–3848 (2001).
   PubMed Web of Science ®Google Scholar
• Hassoun H, Reich L, Klimek VM et al. Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. Br. J. Haematol.132(2), 155–161 (2006).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bertola A, Falco P et al. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol. J.5(4), 318–324 (2004).
   PubMedGoogle Scholar
• Dimopoulos MA, Zervas K, Kouvatseas G et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann. Oncol.12(7), 991–995 (2001).
   PubMed Web of Science ®Google Scholar
• Zervas K, Dimopoulos MA, Hatzicharissi E et al. Greek Myeloma Study Group. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a Phase II multicenter study. Ann. Oncol.15(1), 134–138 (2004).
   PubMed Web of Science ®Google Scholar